Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:application |
used in drug development
|
| gptkbp:avionics |
several analogs developed
|
| gptkbp:chemicalFormula |
contains a triazine ring
C12H15N3O3S considered safe for laboratory use has a melting point of 150-155°C triazine derivatives |
| gptkbp:clinicalTrials |
clinical significance yet to be established
potential use in combination therapies undergoing phase I trials |
| gptkbp:collaborations |
collaborations with multiple universities
may have synergistic effects with other drugs |
| gptkbp:compatibleWith |
bioavailability not yet determined
inhibitor of specific kinases |
| gptkbp:competitors |
potential market in personalized medicine
|
| gptkbp:composedOf |
via multi-step organic synthesis
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:drugInterdiction |
under investigation
|
| gptkbp:environmentalImpact |
low environmental impact expected
low toxicity in preliminary studies |
| gptkbp:financial_aid |
stable under recommended storage conditions
|
| gptkbp:financialPerformance |
protected under international patent law
|
| gptkbp:firstClaim |
future applications in other therapeutic areas
|
| gptkbp:hasResearchInterest |
market research ongoing
|
| gptkbp:historicalResearch |
future research planned for other diseases
part of collaborative research projects |
| https://www.w3.org/2000/01/rdf-schema#label |
WPC-772
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:market |
high market potential in oncology
|
| gptkbp:marketSegment |
not commercially available
|
| gptkbp:origin |
N-(4-(4-(dimethylamino)phenyl)-6-methyl-1,3,5-triazin-2-yl)benzamide
|
| gptkbp:patentAssignee |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:patentStatus |
patented
|
| gptkbp:productionCompany |
currently in preclinical development
|
| gptkbp:regulatoryCompliance |
awaiting regulatory approval
|
| gptkbp:relatedPatent |
WPC-771
|
| gptkbp:releaseYear |
2010
|
| gptkbp:research |
funded by government grants
|
| gptkbp:researchAreas |
cancer therapeutics
|
| gptkbp:researchInterest |
adheres to research ethics guidelines
aims to improve cancer treatment outcomes considered an innovative compound expected to have significant research impact facing challenges in formulation development multiple publications in peer-reviewed journals developed_by_XYZ_Research_Institute |
| gptkbp:safetyFeatures |
requires safety data sheet
|
| gptkbp:scientificName |
recognized by the scientific community
|
| gptkbp:searchAndRescueMissions |
ongoing research into its mechanism of action
|
| gptkbp:sideEffect |
minimal side effects reported
|
| gptkbp:storage |
store_at_-20°C
|
| gptkbp:targets |
potential targeted therapy agent
various cancer cell lines |
| gptkbp:triggerType |
inhibits cell proliferation
|
| gptkbp:uses |
research in pharmacology
|
| gptkbp:weight |
283.33 g/mol
|